Search Results

Rentschler Biopharma SE announced that Patrick Cushing, Ph.D., has been promoted to Vice President Operations of Rentschler Biopharma, Inc., the company’s U.S. subsidiary, effective May 1, 2024.

Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal products, announced that Patrick Meyer, Ph.D., has been promoted to Global Head BD Sales and Alliance Management within the business development team, effective June 1, 2024.

Rentschler Biopharma announced that the company’s U.S. subsidiary, Rentschler Biopharma Inc., has been honored with the Gold Award for the Central Massachusetts region in the 20th Annual Team Massachusetts Economic Impact Awards.

Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal products, announced that Senta Brandt has been promoted to the global position of Head of Transformation, effective January 1, 2024.

Rentschler Biopharma SE announced that the company has secured a major client for the new Rentschler Biopharma Manufacturing Center facility at its manufacturing site in Milford, Massachusetts.

Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including Advanced Therapy Medicinal Products, announced that Gunnar Voss von Dahlen has been appointed as Chief Financial Officer, effective December 1, 2023.

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.